These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
335 related articles for article (PubMed ID: 38090576)
1. Advancing CAR-based immunotherapies in solid tumors: CAR- macrophages and neutrophils. Liang Y; Xu Q; Gao Q Front Immunol; 2023; 14():1291619. PubMed ID: 38090576 [TBL] [Abstract][Full Text] [Related]
2. Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors. Sloas C; Gill S; Klichinsky M Front Immunol; 2021; 12():783305. PubMed ID: 34899748 [TBL] [Abstract][Full Text] [Related]
3. Advancing cellular immunotherapy with macrophages. Mishra AK; Malonia SK Life Sci; 2023 Sep; 328():121857. PubMed ID: 37307965 [TBL] [Abstract][Full Text] [Related]
4. Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T. Liu Q; Li J; Zheng H; Yang S; Hua Y; Huang N; Kleeff J; Liao Q; Wu W Mol Cancer; 2023 Feb; 22(1):28. PubMed ID: 36750830 [TBL] [Abstract][Full Text] [Related]
5. Recent Advances in CAR-Based Solid Tumor Immunotherapy. Shin MH; Oh E; Kim Y; Nam DH; Jeon SY; Yu JH; Minn D Cells; 2023 Jun; 12(12):. PubMed ID: 37371075 [TBL] [Abstract][Full Text] [Related]
6. Chimeric antigen receptor-based immunotherapy in breast cancer: Recent progress in China. Yu T; Lu Y; Fang J; Jiang X; Lu Y; Zheng J; Shang X; Shen H; Fu P Cancer; 2024 Apr; 130(S8):1378-1391. PubMed ID: 37950749 [TBL] [Abstract][Full Text] [Related]
7. Manipulating macrophage polarization in cancer patients: From nanoparticles to human chimeric antigen receptor macrophages. Santoni M; Massari F; Montironi R; Battelli N Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188547. PubMed ID: 33932561 [TBL] [Abstract][Full Text] [Related]
8. Sophisticated genetically engineered macrophages, CAR-Macs, in hitting the bull's eye for solid cancer immunotherapy approaches. Unver N Clin Exp Med; 2023 Nov; 23(7):3171-3177. PubMed ID: 37278931 [TBL] [Abstract][Full Text] [Related]
9. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. Pan K; Farrukh H; Chittepu VCSR; Xu H; Pan CX; Zhu Z J Exp Clin Cancer Res; 2022 Mar; 41(1):119. PubMed ID: 35361234 [TBL] [Abstract][Full Text] [Related]
10. Revolution of CAR Engineering For Next-Generation Immunotherapy In Solid Tumors. Yu T; Yu SK; Xiang Y; Lu KH; Sun M Front Immunol; 2022; 13():936496. PubMed ID: 35903099 [TBL] [Abstract][Full Text] [Related]
11. CAR-NK Cells: From Natural Basis to Design for Kill. Khawar MB; Sun H Front Immunol; 2021; 12():707542. PubMed ID: 34970253 [TBL] [Abstract][Full Text] [Related]
12. Bright future or blind alley? CAR-T cell therapy for solid tumors. Zhang K; Chen H; Li F; Huang S; Chen F; Li Y Front Immunol; 2023; 14():1045024. PubMed ID: 36761757 [TBL] [Abstract][Full Text] [Related]
13. Coengineering specificity, safety, and function into T cells for cancer immunotherapy. Giordano Attianese GMP; Ash S; Irving M Immunol Rev; 2023 Nov; 320(1):166-198. PubMed ID: 37548063 [TBL] [Abstract][Full Text] [Related]
14. CAR-macrophage: A new immunotherapy candidate against solid tumors. Chen Y; Yu Z; Tan X; Jiang H; Xu Z; Fang Y; Han D; Hong W; Wei W; Tu J Biomed Pharmacother; 2021 Jul; 139():111605. PubMed ID: 33901872 [TBL] [Abstract][Full Text] [Related]
15. Chimeric antigen receptor-engineered T-cell therapy for liver cancer. Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325 [TBL] [Abstract][Full Text] [Related]
16. Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors. Miao L; Zhang Z; Ren Z; Tang F; Li Y Front Immunol; 2021; 12():687822. PubMed ID: 34093592 [TBL] [Abstract][Full Text] [Related]
17. How to Test Human CAR T Cells in Solid Tumors, the Next Frontier of CAR T Cell Therapy. Cochrane RW; Fiorentino A; Allen E; Robino RA; Quiroga J; Ferreira LMR Methods Mol Biol; 2024; 2748():243-265. PubMed ID: 38070118 [TBL] [Abstract][Full Text] [Related]
18. Engineering chimeric antigen receptor T cells for solid tumour therapy. Liu L; Qu Y; Cheng L; Yoon CW; He P; Monther A; Guo T; Chittle S; Wang Y Clin Transl Med; 2022 Dec; 12(12):e1141. PubMed ID: 36495108 [TBL] [Abstract][Full Text] [Related]
19. Enhancing CAR T-cell therapies against solid tumors: Mechanisms and reversion of resistance. Qin Y; Xu G Front Immunol; 2022; 13():1053120. PubMed ID: 36569859 [TBL] [Abstract][Full Text] [Related]
20. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies. Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]